VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Given Consensus Rating of “Reduce” by Analysts

Shares of VistaGen Therapeutics, Inc. (NASDAQ:VTGN) have been assigned a consensus rating of “Reduce” from the five analysts that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation and four have assigned a hold recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $0.95.

Several brokerages recently weighed in on VTGN. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of VistaGen Therapeutics in a research report on Wednesday, October 8th. William Blair restated a “market perform” rating on shares of VistaGen Therapeutics in a research note on Wednesday, December 17th. Maxim Group reaffirmed a “hold” rating on shares of VistaGen Therapeutics in a research note on Wednesday, December 17th. Stifel Nicolaus downgraded shares of VistaGen Therapeutics from a “buy” rating to a “hold” rating and set a $1.00 target price for the company. in a research report on Wednesday, December 17th. Finally, Wall Street Zen lowered shares of VistaGen Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, December 20th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Millennium Management LLC bought a new position in shares of VistaGen Therapeutics in the third quarter worth $73,000. Bank of America Corp DE grew its position in VistaGen Therapeutics by 926.0% during the 3rd quarter. Bank of America Corp DE now owns 34,657 shares of the company’s stock worth $123,000 after purchasing an additional 31,279 shares in the last quarter. Boothbay Fund Management LLC lifted its stake in VistaGen Therapeutics by 10.8% in the 3rd quarter. Boothbay Fund Management LLC now owns 197,024 shares of the company’s stock worth $699,000 after acquiring an additional 19,166 shares in the last quarter. Schonfeld Strategic Advisors LLC purchased a new position in VistaGen Therapeutics during the third quarter valued at approximately $39,000. Finally, Occudo Quantitative Strategies LP purchased a new stake in shares of VistaGen Therapeutics during the third quarter worth $152,000. 78.39% of the stock is currently owned by hedge funds and other institutional investors.

VistaGen Therapeutics Price Performance

NASDAQ:VTGN traded down $0.04 during trading hours on Friday, reaching $0.66. 1,713,084 shares of the company traded hands, compared to its average volume of 6,226,495. The firm’s 50-day moving average is $3.00 and its 200-day moving average is $3.12. The stock has a market cap of $26.07 million, a P/E ratio of -0.35 and a beta of 0.31. VistaGen Therapeutics has a 1-year low of $0.63 and a 1-year high of $5.14.

VistaGen Therapeutics (NASDAQ:VTGN) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.03). The firm had revenue of $0.26 million for the quarter, compared to analyst estimates of $0.16 million. As a group, research analysts predict that VistaGen Therapeutics will post -1.77 earnings per share for the current year.

About VistaGen Therapeutics

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.